title: Bevacizumab plus cisplatin and helical tomotherapy in treatment of locally advanced nasopharyngeal carcinoma.
abstract: BACKGROUND
  In recent years, chemotherapy, radiotherapy, and targeted drugs have been respectively used in nasopharyngeal carcinoma. In our research, we combined all of them for better curative effects.
  
  
  METHODS
  Thirty patients with histologically confirmed stage III~IV (without distant metastasis) nasopharyngeal carcinoma were recruited between December 2013 and October 2014 with strict eligibility requirements and exclusion criteria. Bevacizumab 5 mg/kg, 80 mg/m(2) cisplatin and 67.5 Gy radiotherapy (helical tomotherapy [TOMO]) was given according to standard treatment protocols.
  
  
  RESULTS
  After 3 months, 24 complete responses (80%) and six partial responses (40%) were observed in our research. Twenty-four patients (80%) experienced oropharyngeal mucositis, 26% patients experienced weight loss caused by pharyngeal pain and dysphagia caused by oropharyngeal mucositis.
  
  
  CONCLUSIONS
  Bevacizumab plus cisplatin and TOMO in treatment of locally advanced nasopharyngeal carcinoma can increase curative effects with low side effects and toxicities.
authors.affiliation: Radiology Department, Cancer Center, The General Hospital of the People's Liberation Army, Beijing, People's Republic of China.
authors.forename: Jianxiong
authors.initials: J
authors.lastname: Li
authors.affiliation: Radiology Department, Cancer Center, The General Hospital of the People's Liberation Army, Beijing, People's Republic of China.
authors.forename: Zhifei
authors.initials: Z
authors.lastname: Zhao
authors.affiliation: Radiology Department, Cancer Center, The General Hospital of the People's Liberation Army, Beijing, People's Republic of China.
authors.forename: Xuan
authors.initials: X
authors.lastname: Wu
authors.affiliation: Department of Oncology, The People's Liberation Army 161 Hospital, Wuhan, People's Republic of China.
authors.forename: Jie
authors.initials: J
authors.lastname: Yao
authors.affiliation: Radiology Department, Cancer Center, The General Hospital of the People's Liberation Army, Beijing, People's Republic of China.
authors.forename: Lin
authors.initials: L
authors.lastname: Ma
authors.affiliation: Radiology Department, Cancer Center, The General Hospital of the People's Liberation Army, Beijing, People's Republic of China.
authors.forename: Rui
authors.initials: R
authors.lastname: Ye
authors.affiliation: Radiology Department, Cancer Center, The General Hospital of the People's Liberation Army, Beijing, People's Republic of China.
authors.forename: Baolong
authors.initials: B
authors.lastname: Niu
authors.affiliation: Radiology Department, Cancer Center, The General Hospital of the People's Liberation Army, Beijing, People's Republic of China.
authors.forename: Lanqing
authors.initials: L
authors.lastname: Liang
authors.affiliation: Radiology Department, Cancer Center, The General Hospital of the People's Liberation Army, Beijing, People's Republic of China.
authors.forename: Xiao
authors.initials: X
authors.lastname: Zhao
authors.affiliation: Radiology Department, Cancer Center, The General Hospital of the People's Liberation Army, Beijing, People's Republic of China.
authors.forename: Qianqian
authors.initials: Q
authors.lastname: Wang
keywords: bevacizumab; cisplatin; helical tomotherapy (TOMO); nasopharyngeal carcinoma